Cor Vasa 2020, 62(5):470-472 | DOI: 10.33678/cor.2020.067

Atrial fibrillation and thrombophilia. DOAC as a valid alternative? A clinical case

Claudia Morabito^a, Matteo Casale^b, Pasquale Crea^a, Silvia Morabito^a, Luca Zappia^a, Roberto Licordari^a, Nunzio Antonio Giovanni Fichera^a, Arianna D'Angelo^a, Alessandro Migliorato^a, Francesco Luzza^a, Giuseppe Dattilo^a

^a Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

^b Operative Unit of ICCU and Cardiology Hospital, "S. Maria della Misericordia", ASUR Marche - Area Vasta 1, Urbino, Italy

Oral anticoagulation is a milestone in the management of atrial fibrillation (AF). In complex settings, involving some kinds of thrombophilia, a condition predisposing to higher risk of thromboembolism, warfarin can be ineffective. Direct oral anticoagulants (DOACs) demonstrated to be a valid therapeutic option; in particular edoxaban proved to be effective and safe. We show the case of a man with AF and thrombophilia who developed a thrombus in the left atrial appendage (LAA) despite anticoagulant therapy with warfarin, subsequently treated with edoxaban.

Keywords: Atrial fibrillation, Direct oral anticoagulants, Edoxaban, Thrombophilia

Received: June 30, 2020; Revised: June 30, 2020; Accepted: July 5, 2020; Published: November 1, 2020  Show citation